4.7 Review

Update on blepharospasm -: Report from the BEBRF International Workshop

Journal

NEUROLOGY
Volume 71, Issue 16, Pages 1275-1282

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000327601.46315.85

Keywords

-

Funding

  1. NIH Intramural Program
  2. Control of eyelids in normal and pathological states [EY07391]
  3. Advanced Neuromodulation Systems
  4. Allergan, Inc.
  5. Boehringer-Ingelheim
  6. Ceregene, Inc.
  7. EMD
  8. Eisai
  9. Ipsen Limited
  10. Huntington's Disease Society of America
  11. Kyowa Pharmaceuticals
  12. Medtronic
  13. Merz Pharmaceuticals
  14. National Institutes of Health
  15. National Parkinson Foundation
  16. Novartis
  17. Ortho-McNeil
  18. Parkinson Study Group
  19. Prestwick Pharmaceuticals
  20. Schering
  21. Schwarz Pharma/UCB
  22. Teva

Ask authors/readers for more resources

This review updates understanding and research on blepharospasm, a subtype of focal dystonia. Topics covered include clinical aspects, pathology, pathophysiology, animal models, dry eye, photophobia, epidemiology, genetics, and treatment. Blepharospasm should be differentiated from apraxia of eyelid opening. New insights into pathology and pathophysiology are derived from different types of imaging, including magnetic resonance studies. Physiologic studies indicate increased plasticity and trigeminal sensitization. While botulinum neurotoxin injections are the mainstay of therapy, other therapies are on the horizon.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available